"Ribose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pentose active in biological systems usually in its D-form.
| Descriptor ID |
D012266
|
| MeSH Number(s) |
D09.947.875.627.651
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribose".
Below are MeSH descriptors whose meaning is more specific than "Ribose".
This graph shows the total number of publications written about "Ribose" by people in this website by year, and whether "Ribose" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribose" by people in Profiles.
-
Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Nature. 2023 06; 618(7963):151-158.
-
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecol Oncol. 2023 03; 170:172-178.
-
Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges. Cancer Treat Res. 2023; 186:143-170.
-
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
-
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023 01 01; 41(1):107-116.
-
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. JCO Precis Oncol. 2022 06; 6:e2100531.
-
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecol Oncol. 2022 07; 166(1):117-125.
-
Associations of Poly (ADP-Ribose) Polymerase1 abundance in calf skeletal muscle with walking performance in peripheral artery disease. Exp Gerontol. 2020 10 15; 140:111048.
-
Utilizing Ribose Compounds: How Bacteroides PUL It Off. Cell Host Microbe. 2020 01 08; 27(1):6-8.
-
Single base resolution mapping of 2'-O-methylation sites in human mRNA and in 3' terminal ends of small RNAs. Methods. 2019 03 01; 156:85-90.